<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04258657</url>
  </required_header>
  <id_info>
    <org_study_id>BFH-GCCT</org_study_id>
    <nct_id>NCT04258657</nct_id>
  </id_info>
  <brief_title>Neoadjuvant Chomotherapy With Paclitaxel-albumin and S-1 for Advanced Gastric Cancer</brief_title>
  <official_title>Neoadjuvant Chomotherapy With Paclitaxel-albumin and S-1 for Advanced Gastric Cancer</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Beijing Friendship Hospital</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Beijing Friendship Hospital</source>
  <oversight_info>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This is a interventional clinical trial to assess the efficacy and safety of combinational
      therapy of paclitaxel-albumin and S-1 for the neoadjuvant chemotherapy of advanced gastric
      cancer.
    </textblock>
  </brief_summary>
  <overall_status>Not yet recruiting</overall_status>
  <start_date type="Anticipated">March 1, 2020</start_date>
  <completion_date type="Anticipated">December 31, 2022</completion_date>
  <primary_completion_date type="Anticipated">December 31, 2022</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>DFS</measure>
    <time_frame>3-year</time_frame>
    <description>disease free survival</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>ORR</measure>
    <time_frame>3-year</time_frame>
    <description>objective response rate</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>OS</measure>
    <time_frame>3-year</time_frame>
    <description>overall survival</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">20</enrollment>
  <condition>Gastric Cancer</condition>
  <arm_group>
    <arm_group_label>Paclitaxel-albumin and S-1</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>paclitaxel-albumin and S-1</intervention_name>
    <description>neoadjuvant chomotherapy with paclitaxel-albumin and S-1 for advanced gastric cancer</description>
    <arm_group_label>Paclitaxel-albumin and S-1</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. pathologically diagnosed gastric adenocarcinoma

          2. Type II and III esophageal-gastric-junction malignancy

          3. AJCC stage II-III

          4. No contraindications for surgery, radical resection can be expected

          5. KPS&gt;60; ECOG score:0-2

          6. Expactant survival period&gt;6 months

          7. Age 20~75

          8. No other major health issues

          9. Lab results within 7 days before inclusion must satisfy:

               1. neutrophil≥1.5×109/L

               2. PLT≥100×109/L

               3. hemogloblin≥90g/L

               4. ALT,AST&lt;1.5 upper limit

               5. Tbil≤1.0×UNL

               6. serum creatinine&lt;1.5×UNL

               7. PT-INR/PTT&lt;1.7 upper limit

         10. with measurable lesion according to RECIST1.1 criteria

         11. with consent

         12. co-operative

        Exclusion Criteria:

          1. with other major health issue

          2. allergic to relevant drugs

          3. experienced any other drug therapy with 4 weeks before inclusion

          4. experienced any drug therapy for gastric cancer at anytime

          5. diagnosed with any other malignancy within the past 5 years

          6. women at child-bearing age; pregnant or breast-feeding women

          7. with severe heart disease

          8. with upper GI digestion or disrupted absorption

          9. with peripheral neural disease

         10. with transplated organs or organs having been resected for transplantation

         11. known DPD deficiency

         12. with uncontrolled infection
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>N/A</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Wei Deng</last_name>
    <role>Study Director</role>
    <affiliation>Beijing Friendship Hospital</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Zhongtao Zhang</last_name>
    <phone>8618811792819</phone>
    <phone_ext>8618811792819</phone_ext>
    <email>zhongtao.z@139.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>Zhongtao Zhang</name>
      <address>
        <city>Beijing</city>
        <state>Beijing</state>
        <zip>100050</zip>
        <country>China</country>
      </address>
    </facility>
    <contact>
      <last_name>Zhongtao Zhang</last_name>
      <phone>8618811792819</phone>
      <phone_ext>8618811792819</phone_ext>
      <email>zhongtao.z@139.com</email>
    </contact>
  </location>
  <location_countries>
    <country>China</country>
  </location_countries>
  <verification_date>February 2020</verification_date>
  <study_first_submitted>February 5, 2020</study_first_submitted>
  <study_first_submitted_qc>February 5, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">February 6, 2020</study_first_posted>
  <last_update_submitted>February 5, 2020</last_update_submitted>
  <last_update_submitted_qc>February 5, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">February 6, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Beijing Friendship Hospital</investigator_affiliation>
    <investigator_full_name>Zhongtao Zhang</investigator_full_name>
    <investigator_title>Professor</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Stomach Neoplasms</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Paclitaxel</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>Undecided</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

